Sanofi has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells.
The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well, Sanofi said.
Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.
Tidal Therapeutics was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures, and AbbVie Ventures. The company utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells.
Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications, Sanofi explained in its press release.